The principal goal of this project is to understand the impact of HIV envelope-mediated signaling on viral replication and immune dysfunction. This information may facilitate the discovery of new strategies for the treatment of HIV infection. HIV envelope proteins, which are displayed on the surface of viral particles, bind to two receptors on T-lymphocytes in order to infect those cells. Initially envelope proteins on the outer surface of virions dock with the CD4 receptor, and subsequently they engage a co-receptor, either CCR5 or CXCR4. Envelope engagement of each of these receptors results in signal transduction; however the consequences associated with those signals is only partially understood. In previous studies we demonstrated that HIV envelope-mediated signaling induces several biological responses in primary T-cells and macrophages, including the induction of expression of proinflammatory cytokines and increased rates of apoptosis. ? ? To obtain a more complete picture of the effect of envelope on the function and metabolic state of peripheral blood mononuclear cells (PBMCs), we developed an experimental strategy in which PBMCs from healthy donors were exposed to HIV envelope, and changes in the transcriptional program were determined using high-density oligonucleotide microarrays. HIV envelopes derived from different isolates vary in their primary sequence. In order to understand the relevance of sequence variation to envelope signaling, a panel of envelopes representing each of the five major sub-types of HIV was generated. Because envelopes vary with respect to their co-receptor usage, we included both CCR5 and CXCR4-specific envelopes. The panel of recombinant gp120 proteins was then exposed to primary PBMCs as well as macrophages. HIV envelope induced the expression of cytokines, chemokines, kinases, and transcription factors associated with antigen-specific T cell activation. Of note, these events occurred in the absence of cellular proliferation. It is possible that gp120-mediated effects increase the susceptibility of target cells to productive infection and contribute to the low level replication of HIV in cells that do not express markers of activation. Replication in this manner may contribute to the establishment and maintenance of reservoirs of HIV infection.? ? In agreement with the microarray data we demonstrated that HIV envelope induces the replication of HIV from resting CD4+ T cells of HIV-infected patients in the absence of induction of markers of classical T cell activation. These data suggest that HIV virions or free envelope protein induced a level of cellular stimulation that is sufficient for HIV replication, but that is below the threshold required for classic T cell activation. Furthermore, this model suggests that HIV may propagate itself in non-dividing cells that have an inherently longer half-life than do classically activated T cells. Because HIV viruses that utilize CXCR4 rather than CCR5 are associated with rapid disease progression we extended our analysis to compare and evaluate the differential effect of CCR5- vs. CXCR4-specific envelope proteins with respect to signal transduction and changes in cellular transcription. Interestingly, we found that genes associated with protein modification were differentially modulated by CCR5- vs. CXCR4-specific envelope proteins. This information may help us understand why CCR5-specific viruses are preferentially transmitted, and predominate early in disease, and why, in some individuals, CXCR4-specific envelopes predominate late in disease and are associated with increased the rates of disease progression. Answering these questions may aid us in designing better anti-HIV treatments and effective vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000887-06
Application #
7303861
Study Section
(LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kelley, James M; Daley, George Q (2013) Hematopoietic defects and iPSC disease modeling: lessons learned. Immunol Lett 155:18-20
Garron, Marie-Line; Arthos, James; Guichou, Jean-Francois et al. (2008) Structural basis for the interaction between focal adhesion kinase and CD4. J Mol Biol 375:1320-8
Arthos, James; Cicala, Claudia; Martinelli, Elena et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9:301-9
Martinelli, Elena; Cicala, Claudia; Van Ryk, Donald et al. (2007) HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104:3396-401
Cocklin, Simon; Gopi, Hosahudya; Querido, Bianca et al. (2007) Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol 81:3645-8
Cicala, Claudia; Arthos, James; Censoplano, Nina et al. (2006) HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology 345:105-14
Cicala, Claudia; Arthos, James; Martinelli, Elena et al. (2006) R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc Natl Acad Sci U S A 103:3746-51
Snyder, Greg A; Ford, Jennifer; Torabi-Parizi, Parizad et al. (2005) Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor. J Virol 79:4589-98
Gupta, Neil; Arthos, James; Khazanie, Prateeti et al. (2005) Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 332:491-7
Wang, Shixia; Arthos, James; Lawrence, John M et al. (2005) Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79:7933-7

Showing the most recent 10 out of 19 publications